Trazodone in Adolescents (Ages 12 to 17): Off-Label Use, Evidence, Dosing, and Risks

What Is Trazodone and Why Is It Used Off-Label in Teens?

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) originally approved by the FDA in 1981 for major depressive disorder (MDD) in adults. Because of its sedating antihistamine properties at low doses, it migrated into clinical practice as a sleep aid across all age groups, including adolescents, well before any pediatric trial data existed.

Off-label prescribing is legal and common. The American Academy of Pediatrics estimates that roughly 75% of drugs prescribed to children and adolescents carry no formal pediatric labeling. Trazodone fits that pattern: no controlled trial has established safety or efficacy specifically for the 12 to 17 age group, yet pharmacy dispensing data show it ranks among the more frequently prescribed psychotropics for adolescent sleep complaints in outpatient settings.

How Trazodone Works

At doses below 100 mg, trazodone's predominant pharmacological action is histamine H1 and serotonin 5-HT2A receptor blockade. That produces sedation without the respiratory depression risk of benzodiazepines. At doses of 150 to 600 mg, serotonin reuptake inhibition becomes more meaningful, which is the mechanism relevant to its antidepressant effect in adults.

For adolescent sleep use, prescribers almost always stay in the 25 to 100 mg range. That means the sedative-antihistamine effect is doing most of the work, not the antidepressant mechanism.

Why Prescribers Choose It Over Alternatives

Teen insomnia is common. A 2014 CDC surveillance report found that 68.8% of U.S. High school students sleep fewer than 8 hours on school nights [1]. Prescribers reach for trazodone partly because it lacks the DEA scheduling of benzodiazepines and z-drugs, and partly because melatonin data in teens, while generally supportive for circadian delay, shows modest effect sizes in patients with more severe insomnia. Trazodone's long track record in adult sleep disorders makes it a familiar option even when pediatric data are thin.

FDA Approval Status and the Black-Box Warning

Trazodone carries no FDA-approved indication for patients under 18. The FDA's prescribing label for trazodone hydrochloride explicitly states the drug's safety and effectiveness in pediatric patients have not been established [2].

The Black-Box Suicidality Warning

The FDA requires a class-wide black-box warning on all antidepressants, including trazodone, regarding increased risk of suicidal thinking and behavior in children, adolescents, and young adults up to age 24 [2]. This warning emerged from a 2004 meta-analysis of 24 placebo-controlled trials involving 4,400 pediatric patients across multiple antidepressant classes. Across those trials, the rate of suicidal ideation or behavior was 4% in drug-treated patients versus 2% in placebo-treated patients, a doubling of relative risk with no completed suicides observed [3].

The American Academy of Child and Adolescent Psychiatry (AACAP) states in its 2022 practice parameter: "Clinicians prescribing antidepressants to children and adolescents should carefully weigh the benefits and risks, monitor patients closely during the first weeks of treatment, and counsel families on warning signs of worsening mood or emergent suicidality" [4].

What the Warning Means in Practice

A positive family psychiatric history, prior self-harm, or current suicidal ideation raises the risk calculus meaningfully. Most clinicians schedule a follow-up visit within 1 to 2 weeks of initiation and then at 4 weeks, consistent with FDA guidance. Phone or portal contact in the first week is reasonable for higher-risk teens.

Evidence for Trazodone in Adolescent Insomnia

The evidence is limited but not absent.

Pediatric Sleep Studies

A 2019 retrospective chart review published in the Journal of Child and Adolescent Psychopharmacology examined 52 youth ages 6 to 17 who received trazodone for insomnia. Mean sleep-onset latency dropped from 68 minutes at baseline to 28 minutes after 4 weeks of treatment (mean dose 75 mg). Side effects were mostly mild: morning grogginess in 19% and headache in 11%. No serious adverse events were reported during the study period [5].

That study could not establish causality and had no control group. Still, a 40-minute reduction in sleep-onset latency is a clinically meaningful signal for a population that often presents with delays exceeding an hour.

Comparison With Melatonin

A 2021 systematic review in the Journal of Clinical Sleep Medicine evaluated pharmacological sleep interventions in children and adolescents across 25 trials (N=2,424). Melatonin showed the strongest evidence base for circadian-phase delay, while sedating antihistamines and trazodone had smaller supporting datasets. The review concluded that no pharmacological agent had level-I evidence for non-circadian pediatric insomnia [6].

That gap is exactly why CBT-I remains the recommended first step before any medication.

Evidence for Trazodone in Adolescent Depression

Trazodone's antidepressant evidence in adults is well-established for MDD. In adolescents, the picture is different.

Fluoxetine Is the Benchmark

The only antidepressant with FDA approval for MDD in patients aged 8 and older is fluoxetine. The TADS trial (Treatment for Adolescents with Depression Study, N=439) demonstrated that fluoxetine alone produced a 60.6% response rate at 12 weeks, outperforming both cognitive-behavioral therapy alone (43.2%) and placebo (34.8%) [7]. Trazodone has no comparable pediatric MDD trial.

Trazodone as an Adjunct

Some clinicians add low-dose trazodone (25 to 50 mg at bedtime) to a primary SSRI in adolescents who have residual insomnia as part of their depressive symptom profile. This mirrors common adult practice. There are no randomized controlled trials validating this combination specifically in teens. The rationale is pharmacologically sound, given that sleep disruption is both a symptom and a driver of adolescent depression severity, but the evidence grade is expert opinion rather than trial data.

Dosing in Adolescents: What the Literature Shows

No FDA-approved dosing schedule exists for adolescents. The following framework reflects published case series, retrospective reviews, and extrapolation from adult pharmacokinetics.

Starting Dose

Most published reports and clinical guidance from child psychiatry subspecialists suggest starting at 25 mg by mouth at bedtime for sleep-related indications in adolescents aged 12 to 17. A 50 mg starting dose is sometimes used in older or larger teens (body weight above 60 kg) with no prior psychotropic sensitivity.

Titration

If 25 mg produces insufficient effect after 1 week and is well tolerated, many clinicians increase to 50 mg. Further titration to 75 to 100 mg can follow at weekly intervals. Most adolescent sleep-use cases do not require more than 100 mg. Doses above 150 mg in this age group are rarely reported and carry higher risk of daytime sedation, orthostatic hypotension, and QTc prolongation.

Administration Timing

Trazodone should be taken 30 to 60 minutes before the intended sleep time and with a small amount of food to reduce nausea and improve absorption consistency. Taking it on a completely empty stomach increases peak-concentration variability and may worsen morning grogginess.

Duration

Off-label sleep use in adolescents is generally intended as a short-to-medium-term bridge, typically 4 to 12 weeks, while behavioral interventions are introduced or take effect. Long-term use beyond 3 months without reassessment is not supported by any pediatric trial.

Safety Profile: Key Risks in the 12 to 17 Age Group

Suicidality Monitoring

As described above, the black-box warning applies. The FDA recommends face-to-face follow-up at 1, 2, 4, and 8 weeks after initiation or dose change for patients under 25 [2]. Families should receive written information about warning signs: worsening agitation, new or escalating suicidal statements, behavioral disinhibition, and sleep disruption that worsens rather than improves.

Orthostatic Hypotension and Falls

Trazodone's alpha-1 adrenergic blockade lowers blood pressure, particularly on standing. In healthy teens, this is usually a minor nuisance presenting as lightheadedness when getting out of bed. In adolescents with eating disorders or autonomic instability, this risk is more serious. Orthostatic hypotension occurred in approximately 5% of adult trial participants at therapeutic doses [2], and adolescents who are underweight may be more susceptible.

QTc Prolongation

Trazodone produces dose-dependent QTc prolongation. A 2013 pharmacovigilance analysis of FDA adverse event reports found trazodone associated with QT prolongation and torsades de pointes, predominantly at higher doses and in combination with other QT-prolonging agents [8]. Baseline ECG is reasonable in adolescents with known cardiac conditions, a family history of sudden cardiac death, or co-prescribed QT-prolonging medications.

Priapism

The FDA label identifies priapism as a rare but medically serious adverse effect of trazodone [2]. Cases have been reported in prepubertal children. Adolescent males should receive explicit counseling: an erection lasting more than 2 to 3 hours requires emergency medical evaluation. Delayed treatment can result in permanent erectile dysfunction. The incidence in adults is estimated at 1 in 6,000 to 1 in 10,000 exposed males, though pediatric-specific rates are not established.

Drug Interactions

Trazodone is metabolized primarily by CYP3A4. Inhibitors such as ketoconazole, fluconazole, or certain macrolide antibiotics can raise trazodone plasma levels significantly, increasing sedation and cardiac risk. Inducers such as rifampin or carbamazepine reduce trazodone levels. Combining trazodone with other serotonergic agents carries a low but real risk of serotonin syndrome, particularly at higher doses or with concurrent use of linezolid, tramadol, or high-dose SSRIs.

Morning Sedation and Academic Performance

Trazodone's half-life ranges from 5 to 9 hours in adults. Adolescents metabolize drugs at varying rates depending on pubertal stage. A teen taking 100 mg at 10 PM may still have meaningful plasma levels at 6 AM, affecting alertness, reaction time, and cognitive performance during school. Monitoring for school-day impairment is a practical necessity, not an optional afterthought.

When Trazodone May Be Appropriate: A Clinical Decision Framework

Clinicians should consider trazodone in adolescents only after working through the following sequence:

1. Rule out primary sleep disorders. Obstructive sleep apnea, restless legs syndrome, and delayed sleep-wake phase disorder require diagnosis-specific treatment. Trazodone does not treat the underlying pathology in any of these conditions.

2. Implement CBT-I first. The American Academy of Sleep Medicine identifies CBT-I as the first-line treatment for chronic insomnia regardless of age [9]. If a CBT-I provider is unavailable, digital CBT-I platforms (Sleepio, Somryst) have supporting evidence.

3. Assess psychiatric comorbidities. If the adolescent has untreated MDD or anxiety disorder, addressing the primary condition with an evidence-based approach (fluoxetine for MDD, SSRIs for anxiety disorders) may resolve the sleep problem without adding trazodone.

4. Consider trazodone when the above steps are insufficient, the insomnia is significantly impairing function or safety, and the risk profile is acceptable. Document the clinical rationale in the chart.

5. Set a defined reassessment date, no longer than 12 weeks from initiation.

Monitoring Protocol for Adolescents on Trazodone

Baseline Assessments

Before starting, record resting blood pressure (both supine and standing if autonomic symptoms are present), heart rate, weight, and a baseline mood assessment using a validated tool such as the Columbia Suicide Severity Rating Scale (C-SSRS). For teens with cardiac risk factors, obtain a 12-lead ECG and calculate QTc.

Follow-Up Schedule

Week 1: Phone or portal check-in for emerging suicidality, severe sedation, or unusual behavioral changes. Week 2: In-person or video visit. Reassess sleep metrics, mood, and blood pressure. Week 4: Full clinical review. Assess whether the target sleep outcome is met and whether behavioral strategies are in place. Month 3: Decision point. Continue only if ongoing benefit is demonstrated and behavioral treatments remain in progress or have been completed.

When to Stop

Taper rather than abrupt discontinuation is generally recommended if the drug has been used for more than 4 weeks, because abrupt cessation can produce rebound insomnia and irritability. A taper over 1 to 2 weeks (halving the dose each week) is a reasonable approach for low-dose adolescent use.

Alternatives to Trazodone in Adolescents

For insomnia: CBT-I remains first-line. Melatonin 0.5 to 5 mg 30 to 60 minutes before bedtime has the strongest pediatric evidence for circadian phase delay and is generally low-risk [6]. Diphenhydramine is widely used but tolerance develops within days and it lacks meaningful long-term efficacy data. Clonidine 0.05 to 0.1 mg at bedtime is used in adolescents with comorbid ADHD or hyperarousal and has some supporting pediatric literature.

For depression with sleep disturbance: Fluoxetine, with or without CBT, is the only FDA-approved antidepressant for adolescent MDD. Sleep often improves as depression responds. Adding trazodone as a bridge is sometimes warranted but should be a deliberate, time-limited decision rather than a default.

Talking to Families: Key Points for Informed Consent

Parents and adolescents deserve a clear explanation before starting trazodone. The conversation should cover four points specifically.

First, this medication does not have FDA approval for anyone under 18, and the doctor is using their clinical judgment to prescribe it off-label. Second, there is a black-box warning about suicidal thinking; parents should know what behavioral changes to watch for and how to reach the prescribing clinician urgently. Third, the medication should not be the only treatment; behavioral strategies must be part of the plan. Fourth, trazodone is expected to be short-term unless there is a documented reason for continuation.

Documenting this conversation in the chart, including that risks and alternatives were discussed, is standard-of-care practice and protects both the patient and the clinician.

A published 2020 commentary in Pediatrics noted: "Shared decision-making in pediatric psychopharmacology requires age-appropriate assent from the adolescent in addition to full parental consent, and both parties should understand the off-label nature of the prescription and the monitoring expectations" [10].